General Notices

• NIDDK Investigator-Initiated Multi-Center Clinical Studies Revised Guidance
  (NOT-DK-20-051)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

Notice of Changes to Funding Opportunities

• Notice of NIDDK Participation in PA-20-183, Research Project Grant (Parent R01 Clinical Trial Required)
  (NOT-DK-21-004)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of NIDDK Participation in PA-20-184, Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  (NOT-DK-21-005)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice to Extend Expiration Date for PA-18-480 "NICHD Research Project Grant (R01 - Clinical Trial Required)"
  (NOT-HD-20-045)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice to Extend Expiration Date for PA-18-481 "NICHD Small Grant Program (R03 Clinical Trial Optional)"
  (NOT-HD-20-046)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Correction to PAR-21-081 "Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional)" Standard Due Dates Apply
  (NOT-MD-21-009)
  National Institute on Minority Health and Health Disparities
  

• Notice of Change to Budget Information and Key Dates for PAR-20-027, "Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (Collaborative U01 Clinical Trial Not Allowed)"
  (NOT-MH-21-110)
  National Institute of Mental Health
  

• Notice of Extension to PA-18-579, "Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R41/R42 - Clinical Trial Optional)"
  (NOT-MH-21-135)
  National Institute of Mental Health
  

• Notice of Extension to PA-18-566, "Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R43/R44 Clinical Trial Optional)"
  (NOT-MH-21-136)
  National Institute of Mental Health
  

• Notice of Extension to PA-18-567,"Competing Renewal Awards of SBIR Phase IIB Grants for Brain and Behavior Tools (R44-Clinical Trial Optional)"
  (NOT-MH-21-137)
  National Institute of Mental Health
  

• Notice of Extension to PA-18-819, "Lab to Marketplace: Tools for Brain and Behavioral Research (R43/R44 Clinical Trial Optional)"
  (NOT-MH-21-138)
  National Institute of Mental Health
  

• Notice of Extension to PAR-18-430, "Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)"
  (NOT-MH-21-140)
  National Institute of Mental Health
  

• Notice of Cancellation of May 25, 2021 submission date for PAR-20-076 "Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences (T32 Clinical Trial Not Allowed)
  (NOT-NS-21-018)
  National Institute of Neurological Disorders and Stroke
  National Institute on Drug Abuse
  National Institute of General Medical Sciences
  National Institute of Mental Health
  

• Notice of Change to Key Dates for PAR-18-304 "NIH SIREN Neurologic Clinical Trials (U01 Clinical Trial Required)"
  (NOT-NS-21-020)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Correction to NOT-OD-21-020 Application and Submission Information
  (NOT-OD-21-042)
  National Institutes of Health
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34 Clinical Trial Not Allowed)
  (NOT-GM-21-004)
  National Institute of General Medical Sciences
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)
  (NOT-OD-21-044)
  Office of Disease Prevention
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)
  (NOT-OD-21-045)
  Office of Disease Prevention
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Support Global Cancer Stigma Research
  (NOT-CA-21-026)
  National Cancer Institute
  

• Notice of Special Interest (NOSI) for the NEI Anterior Segment Initiative (ASI): Identification and Development of New Biomarkers and Effective methods to Diagnose Dry Eye Disease.
  (NOT-EY-21-007)
  National Eye Institute
  

• Notice of Special Interest: Administrative Supplements for COVID-19 Impacted NIMH Research
  (NOT-MH-21-120)
  National Institute of Mental Health
  

• Notice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis
  (NOT-MH-21-175)
  National Institute of Mental Health
  National Eye Institute
  National Institute on Aging
  National Institute on Drug Abuse
  

Funding Opportunities

• Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)
  (PAR-20-316)
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): September 14, 2021, September 13, 2022, September 12, 2023
  
  

• NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
  (PAR-21-092)
  National Institute on Drug Abuse
  Application Receipt Date(s): July 26, 2021; July 25, 2022; July 25, 2023
  
  

• Music and Health: Understanding And Developing Music Medicine (R21 Clinical Trial Optional)
  (PAR-21-099)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): February 16, 2021, February 16, 2022, February 16, 2023
  
  

• Music and Health: Understanding And Developing Music Medicine (R01 Clinical Trial Optional)
  (PAR-21-100)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): February 5, 2021, February 5, 2022, February 5, 2023
  
  

• NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
  (PAR-21-101)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): June 9, 2021, February 17, 2022, October 13, 2022, June 8, 2023 and February 15, 2024
  
  

• NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
  (PAR-21-102)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 5, 2021
  
  

• NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
  (PAR-21-103)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 5, 2021
  
  

• Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R41/R42 - Clinical Trials Optional)
  (RFA-DA-21-015)
  National Institute on Drug Abuse
  Application Receipt Date(s): February 26, 2021
  
  

• Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional)
  (RFA-DA-21-016)
  National Institute on Drug Abuse
  Application Receipt Date(s): February 26, 2021
  
  

• Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
  (RFA-DA-21-031)
  National Institute on Drug Abuse
  Application Receipt Date(s): January 26, 2021
  
  

• Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
  (RFA-DA-21-032)
  National Institute on Drug Abuse
  Application Receipt Date(s): January 26, 2021